Search research articles
Contact Us
Filters
Showing results (11-20 of 14) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 14 results.
Geburtshilfe Und Frauenheilkunde
|
October 1, 1990
[Pregnancy following organ transplantation]
H Kraemer-Hansen, E Goepel, H U Ulmer, et al.
Cancer Research
|
May 1, 1996
Allelic imbalance on chromosome 13q: evidence for the involvement of BRCA2 and RB1 in sporadic breast cancer
U Hamann, C Herbold, S Costa, et al.
Breast Cancer Research and Treatment
|
December 31, 2010
Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765)
A Noske, S Loibl, S Darb-Esfahani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 17, 2014
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†
G von Minckwitz, S Loibl, M Untch, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 14) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 14 results.
Geburtshilfe Und Frauenheilkunde
|
October 1, 1990
[Pregnancy following organ transplantation]
H Kraemer-Hansen, E Goepel, H U Ulmer, et al.
Cancer Research
|
May 1, 1996
Allelic imbalance on chromosome 13q: evidence for the involvement of BRCA2 and RB1 in sporadic breast cancer
U Hamann, C Herbold, S Costa, et al.
Breast Cancer Research and Treatment
|
December 31, 2010
Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765)
A Noske, S Loibl, S Darb-Esfahani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 17, 2014
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†
G von Minckwitz, S Loibl, M Untch, et al.
Page
of 2